What is Perspective Therapeutics, Inc.'s Market Cap?

Perspective Therapeutics, Inc.'s Market Cap is $356.2M, based on as-reported figures from SEC (XBRL) filings.

What is Perspective Therapeutics, Inc.'s Enterprise Value?

Perspective Therapeutics, Inc.'s Enterprise Value is $120.9M, based on as-reported figures from SEC (XBRL) filings.

What is Perspective Therapeutics, Inc.'s EV / EBITDA?

Perspective Therapeutics, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is Perspective Therapeutics, Inc.'s Net Income (TTM)?

Perspective Therapeutics, Inc.'s Net Income (TTM) is -$116.4M, based on as-reported figures from SEC (XBRL) filings.

What is Perspective Therapeutics, Inc.'s EBITDA?

Perspective Therapeutics, Inc.'s EBITDA is -$121.2M, based on as-reported figures from SEC (XBRL) filings.

What is Perspective Therapeutics, Inc.'s Diluted EPS (TTM)?

Perspective Therapeutics, Inc.'s Diluted EPS (TTM) is -1.02, based on as-reported figures from SEC (XBRL) filings.

What is Perspective Therapeutics, Inc.'s Net Debt?

Perspective Therapeutics, Inc.'s Net Debt is -$235.3M, based on as-reported figures from SEC (XBRL) filings.

Perspective Therapeutics, Inc. (CATX) Financial Statements

Perspective Therapeutics, Inc.

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG001S5Q300

XASE · usd

3.12▼ 0.02 (-0.64%)

As of 2026-09-08

Valuation

Market Cap

Enterprise Value

Trailing P/E—

Price / Sales—

EV / Revenue—

EV / EBITDA

Financial Highlights

Revenue (TTM)—

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin—

Net Debt

Trading Information

Previous Close3.14

Day's Range3.02 – 3.18

52-Week Range1.96 – 6.16

Volume1.1M

Avg Volume1.1M

Share Statistics

Shares Outstanding

Employees166

ExchangeXASE

Listed2003-12-29

Share count as of August 5, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Perspective Therapeutics, Inc. (CATX)

What is Perspective Therapeutics, Inc.'s Market Cap?: Perspective Therapeutics, Inc.'s Market Cap is $356.2M, based on as-reported figures from SEC (XBRL) filings.
What is Perspective Therapeutics, Inc.'s Enterprise Value?: Perspective Therapeutics, Inc.'s Enterprise Value is $120.9M, based on as-reported figures from SEC (XBRL) filings.
What is Perspective Therapeutics, Inc.'s EV / EBITDA?: Perspective Therapeutics, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Perspective Therapeutics, Inc.'s Net Income (TTM)?: Perspective Therapeutics, Inc.'s Net Income (TTM) is -$116.4M, based on as-reported figures from SEC (XBRL) filings.
What is Perspective Therapeutics, Inc.'s EBITDA?: Perspective Therapeutics, Inc.'s EBITDA is -$121.2M, based on as-reported figures from SEC (XBRL) filings.
What is Perspective Therapeutics, Inc.'s Diluted EPS (TTM)?: Perspective Therapeutics, Inc.'s Diluted EPS (TTM) is -1.02, based on as-reported figures from SEC (XBRL) filings.
What is Perspective Therapeutics, Inc.'s Net Debt?: Perspective Therapeutics, Inc.'s Net Debt is -$235.3M, based on as-reported figures from SEC (XBRL) filings.